Thyroid Cancer
Conditions
Keywords
nodal metastases, 17-538, Memorial Sloan Kettering Cancer Center
Brief summary
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
Interventions
DIAGNOSTIC_TESTCerenkov luminescence imaging.
Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant is 18 years of age or old * Participant must meet one of the following: * Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I * Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan * Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra * Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or \[18f\]-PARPi PET scan in the Nuclear Medicine Clinic * Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic
Exclusion criteria
* Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes * Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80% | Through study completion, an average of 24 hours | The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJan Grimm, MD, PhD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed